Across TCGA pan-cancer cohorts, MTND5P25 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MTND5P25’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where MTND5P25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTND5P25 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

CHOL, STAD, and PAAD are the cancer types where MTND5P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTND5P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	II,III,IV	+0.445	<.001	4	view →
STAD	All	All	+0.214	.004	4	view →
PAAD	Female	All	−0.315	.006	2	view →
COAD	Female	II,III,IV	+0.121	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MTND5P25 RNA expression & survival · all MTND5P25 data types